| 1 |
国家卫生健康委员会. 国家卫生健康委关于新型冠状病毒肺炎暂命名事宜的通知[EB/OL].(2020-02-07)[2020-06-23].
URL
|
| 2 |
国家卫生健康委员会.新型冠状病毒感染的肺炎诊疗方案(试行第七版) [EB/OL].(2020-03-03)[2020-06-23].
URL
|
| 3 |
国家卫生健康委员会.中华人民共和国国家卫生健康委员会公告[EB/OL].(2020-01-20)[2020-06-23].
URL
|
| 4 |
世界卫生组织WHO. 关于2019新型冠状病毒疫情的《国际卫生条例(2005)》突发事件委员会第二次会议的声明[EB/OL].(2020-01-30). [2020-06-23].
URL
|
| 5 |
Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)[J]. Int J Surg, 2020, 76:71-76.
|
| 6 |
Chen W, Peter WH, Frederick GH, et al. A novel coronavirus outbreak of global health concern[J]. Lancet, 2020, 395(10223):470-473.
|
| 7 |
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733.
|
| 8 |
Vincent JM, Koopmans M, Doremalen NV, et al. A novel coronavirus emerging in China-key questions for impact assessment[J]. N Engl J Med, 2020, 382(8):692-694.
|
| 9 |
Xu Z, Lei S, Wang YJ, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422.
|
| 10 |
Lee KY. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy[J]. Int J Mol Sci, 2017, 18(2):388.
|
| 11 |
Chen NS, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, China:a descriptive study[J]. Lancet, 2020, 395(10223):507-513.
|
| 12 |
Bauer TT, Ewig S, Rodloff AC, et al. Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data[J]. Clin Infect Dis, 2006, 43(6):748-756.
|
| 13 |
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in wuhan, China[J]. Lancet, 2020, 395(10223):497-506.
|
| 14 |
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China[J]. JAMA, 2020, 323(11):1061-1069.
|
| 15 |
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1):47-62.
|
| 16 |
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab[J]. Proc Natl Acad Sci U S A, 2020, 117(20): 10970-10975.
|
| 17 |
A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia（COVACTA) (EB/OL) (2020-03-25) [2020-06-23].
URL
|
| 18 |
William GG, Subbarao K, Brian M, et al. Mechanisms of host defense following severe acute respiratory Syndrome-Coronavirus (SARS-CoV) pulmonary infection of mice[J]. J Immunol, 2004, 173(6):4030-4039.
|
| 19 |
Jansan CA, de Geus ED, van Haarlem DA, et al. Differential lung NK cell responses in avian influenza virus infected chickens correlate with pathogenicity[J]. Sci Rep, 2013, 3(1):2478.
|
| 20 |
Parsons MS, Boulet S, Song R, et al. Mind the gap: lack of association between KIR3DL1*004/HLA-Bw4-induced natural killer cell function and protection from HIV infection[J]. J Infect Dis, 2010, 202 Suppl 3: S356-360.
|
| 21 |
Sarvaria A, Jawdat D, Madrigal JA, et al. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications[J]. Front Immunol, 2017, 8:329.
|
| 22 |
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8(4):315-317.
|
| 23 |
Krampera M, Galipeau J, Shi Y, et al. Immunological characterization of multipotent mesenchymal stromal cells--The international society for cellular therapy(ISCT)working proposal[J]. Cytotherapy, 2013, 15(9):1054-1061.
|
| 24 |
Loy H, Kuok DIT, Hui KPY, et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza a(H5N1) virus-associated acute lung injury[J]. J Infect Dis, 2019, 219(2):186-196.
|
| 25 |
Lee JW, Fang X, Krasnodembskaya A, et al. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors[J]. Stem Cells, 2011, 29(6):913-919.
|
| 26 |
Broekman W, Khedoe PPSJ, Schepers K, et al. Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?[J]. Thorax, 2018, 73(6):565-574.
|
| 27 |
Chuang HM, Shih TE, Lu KY, et al. Mesenchymal stem cell therapy of pulmonary fibrosis: improvement with target combination[J]. Cell Transplant, 2018, 27(11): 1581-1587.
|
| 28 |
Fernández Vallone VB, Romaniuk MA, Choi H, et al. Mesenchymal stem cells and their use in therapy: What has been achieved?[J]. Differentiation, 2013, 85(1-2):1-10.
|
| 29 |
Fayyad-Kazan H, Faour WH, Badran B, et al. The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria[J]. Inflamm Res, 2016, 65(6):501-510.
|
| 30 |
Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases[J]. Nat Rev Nephrol, 2018, 14(8):493-507.
|
| 31 |
Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention[J]. JAMA, 2020. doi: 10.1001/jama.2020.2648. Online ahead of print. |
| 32 |
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease[J]. Nat Rev Immunol, 2008, 8(9):726-736.
|
| 33 |
Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells[J]. Blood, 2007, 110(10):3499-3506.
|
| 34 |
Zhou YY, Yamamoto Y, Xiao ZD, et al. The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity[J]. J Clin Med, 2019, 8(7):1025.
|
| 35 |
Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities[J]. Cell Stem Cell, 2018, 22(6):824-833.
|
| 36 |
Uccelli A, Nicole Kerlero de Rosbo. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways[J]. Ann N Y Acad Sci, 2015, 1351(1):114-126.
|
| 37 |
Zheng GP, Ge MH, Qiu G, et al. Mesenchymal stromal cells affect disease outcomes via macrophage polarization[J]. Stem Cells Int, 2015, 2015:989473.
|
| 38 |
Ðokić JM, Tomić SZ, Čolić MJ. Cross-talk between mesenchymal stem/stromal cells and dendritic cells[J]. Curr Stem Cell Res Ther, 2016, 11(1): 51-65.
|
| 39 |
Li N, Hua JL. Interactions between mesenchymal stem cells and the immune system[J]. Cellular and Molecular Life Sciences, 2017, 74(13):2345-2360.
|
| 40 |
Liu GY, Wang LH, Pang TX, et al. Umbilical cord-derived mesenchymal stem cells regulate thymic epithelial cell development and function in Foxn1 (-/-) mice[J]. Cell Mol Immunol, 2014, 11(3):275-284.
|
| 41 |
Li B, Zhang H, Zeng M, et al. Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharide-induced apoptosis partially by inhibiting the Wnt/β-catenin pathway[J]. Cell Biol Int, 2015, 39(2):192-200.
|
| 42 |
Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung[J]. Proc Natl Acad Sci U S A, 2009, 106(38):16357-16362.
|
| 43 |
Yi Y, Hu SL, Xu XP, et al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo[J]. Mediators Inflamm, 2016, 2016: 2347938. Published online 2016 May 24. doi: 10.1155/2016/2347938. |
| 44 |
Megan O, Marius AM, Arul V, et al. Late rescue therapy with Cord-Derived mesenchymal stromal cells for established lung injury in experimental bronchopulmonary dysplasia[J]. Stem Cells Dev, 2020, 29(6):364-371.
|
| 45 |
Kwon JH, Miyeon K, Yun KB, et al. Decorin secreted by human umbilical cord Blood-Derived mesenchymal stem cells induces macrophage polarization via CD44 to repair hyperoxic lung injury[J]. Int J Mol Sci, 2019, 20(19):4815.
|
| 46 |
Hostettler KE, Gazdhar A, Khan P, et al. Multipotent mesenchymal stem cells in lung fibrosis[J]. PLoS One, 2017, 12(8):e0181946.
|
| 47 |
El-Tantawy HW, Ekram Nemr Abd Al Haleem. Therapeutic effects of stem cell on hyperglycemia, hyperlipidemia, and oxidative stress in alloxan-treated rats[J]. Mol Cell Biochem, 2014, 391(1/2):193-200.
|
| 48 |
Radwan SM, Ghoneim D, Salem M, et al. Adipose tissue-derived mesenchymal stem cells protect against Amiodarone-Induced lung injury in rats[J]. Appl Biochem Biotechnol, 2020191(3):1027-1041.
|
| 49 |
Mahmoudi T, Kamal A, Bashiri H, et al. Hydrogen peroxide preconditioning promotes protective effects of umbilical cord vein mesenchymal stem cells in experimental pulmonary fibrosis[J]. Adv Pharm Bull, 2020, 10(1):72-80.
|
| 50 |
Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung[J]. Am J Respir Cell Mol Biol, 2005, 33(2):145-152.
|
| 51 |
Neuringer IP, Randell SH. Stem cells and repair of lung injuries[J]. Respir Res, 2004, 5(1):6.
|
| 52 |
Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study[J]. Respir Res, 2014, 15(1):39.
|
| 53 |
Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS:a phase 1 clinical trial[J]. Lancet Respir Med, 2015, 3(1):24-32.
|
| 54 |
Michael AM, Carolyn SC, Zhuo HJ, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial[J]. Lancet Respir Med, 2019, 7(2):154-162.
|
| 55 |
Chen J, Hu CX, Chen LJ, et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza a (H7N9) infection: a hint for COVID-19 treatment[J]. Engineering(Beijing), 2020. doi: 10.1016/j.eng.2020.02.006. Online ahead of print. |
| 56 |
Leng ZK, Zhu RJ, Wei H, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia[J]. Aging Dis, 2020, 11(2):216-228.
|
| 57 |
Liang B, Chen JH, Li T, et al. (2020)Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells[J]. 2020, 9(2). doi: 10.12074/202002.00084. |
| 58 |
Li GD, Erik DC. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)[J]. Nat Rev Drug Discov, 2020, 19(3):149-150.
|
| 59 |
中国细胞生物学学会干细胞生物学分会&中华医学会感染病学分会.《干细胞治疗新型冠状病毒肺炎(COVID-19)临床研究与应用专家指导意见》[EB/OL].(2020-03-27)[2020-06-23].
URL
|